Parsatuzumab (RG 7414) is a humanized monoclonal antibody targeting EGFL7, which is also used as an immunomodulator.Parsatuzumab selectively inhibits the interaction between EGFL7 and endothelial cells, and has an inhibitory effect on endothelial growth factor (VEGF).Parsatuzumab has been used in combination with other compounds for a long time. Combined use to study rectal cancer

EGFL7是一种仅限于血管的细胞外基质蛋白，促进内皮细胞的粘附与存活[2]。针对患者来源的异种移植（PDX）细胞，Parsatuzumab在48小时后抑制细胞增殖并增加细胞凋亡[1]。

在多个异种移植和基因工程小鼠肿瘤模型中，Parsatuzumab (anti-EGFL7) 增强了与单药抗VEGF治疗相关的抗血管生成、肿瘤生长控制及生存[1]。在MCL（套细胞淋巴瘤）的小鼠模型中，每周三次通过静脉注射给药 (50 mg/kg; i.v.; 3次/周) 的Parsatuzumab 针对EGFL7，能抑制MCL细胞生长并延长生存期[1]。